Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma
Am J Hematol
.
2021 Sep 1;96(9):E341-E344.
doi: 10.1002/ajh.26255.
Epub 2021 Jun 29.
Authors
Meera Mohan
1
,
Aniko Szabo
1
,
Naveen Yarlagadda
2
,
Sravani Gundarlapalli
3
,
Sharmilan Thanendrarajan
3
,
Samantha Kendrick
4
,
Carolina Schinke
3
,
Daisy Alapat
5
,
Jeffrey Sawyer
3
,
Erming Tian
3
,
Guido Tricot
3
,
Frits van Rhee
3
,
Maurizio Zangari
3
Affiliations
1
Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
2
Division of Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
3
Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
4
Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
5
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
PMID:
34050985
DOI:
10.1002/ajh.26255
No abstract available
Publication types
Letter
MeSH terms
Aged
Bone Marrow / pathology*
Female
Humans
Male
Middle Aged
Multiple Myeloma / diagnosis
Multiple Myeloma / pathology*
Neoplasm, Residual / diagnosis
Neoplasm, Residual / pathology*
Prognosis
Survival Analysis